Managers / Q4 2020 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Summary
Sivik Global Healthcare LLC reported $245M in U.S.-listed holdings across 38 positions for Q4 2020.
Its largest position, JNJ, represents 4.2% of the portfolio.
Compared with Q3 2020, the fund opened 9 new positions and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 95.4% · $234M
- Other · 2.7% · $7M
- ADR · 1.9% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| THCTenet Healthcare Corp | NEW | +170.0K | 170.0K | +$7M | $7M |
| ELVAnthem Inc | NEW | +20.0K | 20.0K | +$6M | $6M |
| CAHCardinal Health Inc | NEW | +100.0K | 100.0K | +$5M | $5M |
| INCYIncyte Corp | NEW | +60.0K | 60.0K | +$5M | $5M |
| GRFSGrifols SA | NEW | +250.0K | 250.0K | +$5M | $5M |
| ELANElanco Animal Health Inc | NEW | +150.0K | 150.0K | +$5M | $5M |
| RGENRepligen Corp | NEW | +15.0K | 15.0K | +$3M | $3M |
| NTRANatera Inc | NEW | +20.0K | 20.0K | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | JNJJohnson & Johnsonhistory → | Cash Securities | 4.17% | $10M | 65.0K |
| 2 | HCAHCA Healthcare Inchistory → | Cash Securities | 4.02% | $10M | 60.0K |
| 3 | REGNRegeneron Pharmaceuticals Inchistory → | Cash Securities | 3.94% | $10M | 20.0K |
| 4 | MCKMcKesson Corphistory → | Cash Securities | 3.90% | $10M | 55.0K |
| 5 | MDTMedtronic PLChistory → | Cash Securities | 3.82% | $9M | 80.0K |
| 6 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 3.77% | $9M | 60.0K |
| 7 | UHSUniversal Health Services Inchistory → | Cash Securities | 3.64% | $9M | 65.0K |
| 8 | DHRDanaher Corphistory → | Cash Securities | 3.62% | $9M | 40.0K |
| 9 | ABTAbbott Laboratorieshistory → | Cash Securities | 3.35% | $8M | 75.0K |
| 10 | IQVIQVIA Holdings Inchistory → | Cash Securities | 3.29% | $8M | 45.0K |
| 11 | SYKStryker Corphistory → | Cash Securities | 3.00% | $7M | 30.0K |
| 12 | BSXBoston Scientific Corphistory → | Cash Securities | 2.93% | $7M | 200.0K |
| 13 | HUMHumana Inchistory → | Cash Securities | 2.93% | $7M | 17.5K |
| 14 | AVTRAvantor Inchistory → | Cash Securities | 2.87% | $7M | 250.0K |
| 15 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.86% | $7M | 80.0K |
| 16 | UNHUnitedHealth Group Inchistory → | Cash Securities | 2.86% | $7M | 20.0K |
| 17 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 2.85% | $7M | 15.0K |
| 18 | MOHMolina Healthcare Inchistory → | Cash Securities | 2.82% | $7M | 32.5K |
| 19 | BDXBecton Dickinson and Cohistory → | Cash Securities | 2.81% | $7M | 27.5K |
| 20 | THCTenet Healthcare Corphistory → | Cash Securities | 2.77% | $7M | 170.0K |
| 21 | Laboratory Corp of America Ho | Cash Securities | 2.70% | $7M | 32.5K |
| 22 | ELVAnthem Inchistory → | Cash Securities | 2.62% | $6M | 20.0K |
| 23 | BAXBaxter International Inchistory → | Cash Securities | 2.45% | $6M | 75.0K |
| 24 | LLYEli Lilly and Cohistory → | Cash Securities | 2.41% | $6M | 35.0K |
| 25 | GHGuardant Health Inchistory → | Cash Securities | 2.36% | $6M | 45.0K |
| 26 | Catalent Inc | Cash Securities | 2.33% | $6M | 55.0K |
| 27 | CAHCardinal Health Inchistory → | Cash Securities | 2.18% | $5M | 100.0K |
| 28 | INCYIncyte Corphistory → | Cash Securities | 2.13% | $5M | 60.0K |
| 29 | Charles River Laboratories In | Cash Securities | 2.04% | $5M | 20.0K |
| 30 | BIOBio-Rad Laboratories Inchistory → | Cash Securities | 1.90% | $5M | 8.0K |
| 31 | GRFSGrifols SAhistory → | Cash Securities | 1.88% | $5M | 250.0K |
| 32 | ELANElanco Animal Health Inchistory → | Cash Securities | 1.88% | $5M | 150.0K |
| 33 | CNCCentene Corphistory → | Cash Securities | 1.84% | $5M | 75.0K |
| 34 | EHCEncompass Health Corphistory → | Cash Securities | 1.52% | $4M | 45.0K |
| 35 | RGENRepligen Corphistory → | Cash Securities | 1.17% | $3M | 15.0K |
| 36 | ACHOwens & Minor Inchistory → | Cash Securities | 1.10% | $3M | 100.0K |
| 37 | NTRANatera Inc | Cash Securities | 0.81% | $2M | 20.0K |
| 38 | ADPTAdaptive Biotechnologies Corp | Cash Securities | 0.48% | $1M | 20.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.